News

Vertex Ventures taps Dropbox exec Domenic Perri as partner

Maryland state pension system commits more than $170 mln to VC

U.S. venture fundraising about to top $40 bln, again

L.A. pension commits to Pear Ventures

LAFPP has committed about $90 million to VC funds so far this year

VC-backed Insitro beefs up team with two new appointments

South San Francisco-based Insitro, a machine-learning driven drug discovery and development company, has appointed Dr. Matthew Rasmussen as vice president of data engineering and Duane Valz as general counsel. Rasmussen joins insitro from Myriad Genetics while Valz worked at Zymergen. Insitro's backers include Alexandria Venture Investments, Bezos Expeditions, Mubadala Investment Company, Two Sigma Ventures and Verily.

CPPIB recruits Facebook’s Monica Adractas to lead VC funds strategy

She helped launch Facebook's Workplace in 2016 and for nearly three years served as a global director.

VC-backed twoXAR adds new SVP to team

Mountain View, California-based twoXAR Inc, an artificial intelligence-driven biopharmaceutical company, has appointed Dr. Allen Poirson as senior vice president of biopharmaceutical business development. Poirson is the former CEO of Sony Biotechnology. TwoXAR's backers included SoftBank Ventures, Andreessen Horowitz, OS Fund, CLI Ventures and the Stanford-StartX Fund.

Emerging manager-focused placement agent Pacenote launches

Pacenote Capital will seek relationships with late-stage venture, as well as independent sponsors and lower-mid market buyout funds.

Emerging manager roundup: Base, Strategic Healthcare and DSG lead quiet two weeks

Emerging venture managers entered September and activity was sparse, as only five emerging managers raised commitments in previous two weeks.

VC-backed Rgenix appoints new chief medical officer

New York City-based Rgenix Inc, a developer of first-in-class small molecule and antibody cancer therapeutics, has named Dr. Robert Wasserman as its new chief medical officer. Recently, Wasserman was chief medical officer at Toronto-based Northern Biologics, a developer of first-in-class immuno-oncology products. Rgenix's backers include Lepu Medical, Oceanpine Capital, WuXi AppTec’s Corporate Venture Fund, Novo Holdings A/S, Sofinnova Partners, Alexandria Venture Investments LLC and the Partnership Fund for New York City.